BioCentury | May 3, 2018
Distillery Therapeutics

Cancer

...Avandia-vaccine-mAb combination in other models of melanoma. GlaxoSmithKline plc markets Avandia for Type II diabetes. BriaCell Therapeutics Corp....
BioCentury | Apr 20, 2018
Clinical News

BriaCell's Bria-IMT leads to tumor regressions in Phase I/IIa for breast cancer

...whole cell vaccine comprising a HER2-positive human breast cancer cell line engineered to produce GM-CSF. BriaCell Therapeutics Corp....
...durability of response Status: Phase I/IIa data Milestone: NA Sandi Wong Bria-IMT, BriaVax (sv-br-1-gm) American Association for Cancer Research BriaCell Therapeutics Corp....
BioCentury | Feb 16, 2017
Clinical News

BriaVax: Ph I/IIa start

...This quarter, BriaCell will begin an open-label, U.S. Phase I/IIa trial to evaluate intradermal BriaVax comprising...
...by local interferon (IFN) alpha in the BriaVax inoculation site 2 and 4 days later. BriaCell Therapeutics Corp....
...responses, partial responses or stable disease Status: Phase I/IIa start Milestone: Start Phase I/IIa (1Q17) Julian Zhu BriaVax SV-BR-1-GM BriaCell Therapeutics Corp....
BioCentury | Sep 5, 2016
Financial News

BriaCell completes private placement of units

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:ANCCF), Berkeley, Calif. Business: Cancer Date completed: 2016-08-19 Type: Private placement of units Raised: C$1.7 million ($1.3 million) Units: 8.5 million Price: C$0.20 Shares after offering: 96.4 million Note: Each unit...
BioCentury | May 9, 2016
Financial News

BriaCell completes private placement of units

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:ANCCF), Los Angeles, Calif. Business: Cancer Date completed: 2016-05-03 Type: Private placement of units Raised: C$650,000 ($517,790) Price: C$0.19 (unit) Shares outstanding prior: 84.7 million Placement agent: H.C. Wainwright Investor: Undisclosed...
BioCentury | May 9, 2016
Financial News

BriaCell completes private placement of units

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:ANCCF), Los Angeles, Calif. Business: Cancer Date completed: 2016-05-03 Type: Private placement of units Raised: C$625,000 ($497,875) Price: C$0.20 (unit) Shares outstanding prior: 84.7 million Note: Each unit comprises a share...
BioCentury | Jun 17, 2015
Company News

Management tracks

...director at Accenture. Former CEO Joseph Wagner became president and CEO of cancer immunotherapy company BriaCell Therapeutics Corp....
Items per page:
1 - 7 of 7
BioCentury | May 3, 2018
Distillery Therapeutics

Cancer

...Avandia-vaccine-mAb combination in other models of melanoma. GlaxoSmithKline plc markets Avandia for Type II diabetes. BriaCell Therapeutics Corp....
BioCentury | Apr 20, 2018
Clinical News

BriaCell's Bria-IMT leads to tumor regressions in Phase I/IIa for breast cancer

...whole cell vaccine comprising a HER2-positive human breast cancer cell line engineered to produce GM-CSF. BriaCell Therapeutics Corp....
...durability of response Status: Phase I/IIa data Milestone: NA Sandi Wong Bria-IMT, BriaVax (sv-br-1-gm) American Association for Cancer Research BriaCell Therapeutics Corp....
BioCentury | Feb 16, 2017
Clinical News

BriaVax: Ph I/IIa start

...This quarter, BriaCell will begin an open-label, U.S. Phase I/IIa trial to evaluate intradermal BriaVax comprising...
...by local interferon (IFN) alpha in the BriaVax inoculation site 2 and 4 days later. BriaCell Therapeutics Corp....
...responses, partial responses or stable disease Status: Phase I/IIa start Milestone: Start Phase I/IIa (1Q17) Julian Zhu BriaVax SV-BR-1-GM BriaCell Therapeutics Corp....
BioCentury | Sep 5, 2016
Financial News

BriaCell completes private placement of units

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:ANCCF), Berkeley, Calif. Business: Cancer Date completed: 2016-08-19 Type: Private placement of units Raised: C$1.7 million ($1.3 million) Units: 8.5 million Price: C$0.20 Shares after offering: 96.4 million Note: Each unit...
BioCentury | May 9, 2016
Financial News

BriaCell completes private placement of units

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:ANCCF), Los Angeles, Calif. Business: Cancer Date completed: 2016-05-03 Type: Private placement of units Raised: C$650,000 ($517,790) Price: C$0.19 (unit) Shares outstanding prior: 84.7 million Placement agent: H.C. Wainwright Investor: Undisclosed...
BioCentury | May 9, 2016
Financial News

BriaCell completes private placement of units

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:ANCCF), Los Angeles, Calif. Business: Cancer Date completed: 2016-05-03 Type: Private placement of units Raised: C$625,000 ($497,875) Price: C$0.20 (unit) Shares outstanding prior: 84.7 million Note: Each unit comprises a share...
BioCentury | Jun 17, 2015
Company News

Management tracks

...director at Accenture. Former CEO Joseph Wagner became president and CEO of cancer immunotherapy company BriaCell Therapeutics Corp....
Items per page:
1 - 7 of 7